Literature DB >> 2312773

Effects of a week's beta-adrenoceptor blockade with atenolol and metoprolol CR/ZOK on the response to exercise in healthy women aged 50 to 70 years.

J Patrick1, J Bassey, J Morrant, I Macdonald.   

Abstract

12 healthy women with a mean age of 60 years (range 50-70 years) were treated with 50 mg atenolol or 100 mg metoprolol CR/ZOK or placebo for 1 week in a double-blind, randomized, cross-over study. Laboratory measurements of the cardiovascular responses to exercise were made 2-4 hours after and again 24 hours after the last tablet. Blood pressure and heart rate at rest were reduced equally by the two beta-adrenoceptor antagonists. The reductions in blood pressure and heart rate during graded exercise and then during prolonged steady treadmill exercise 3-4 hours after the tablet were greater for atenolol than metoprolol CR/ZOK. The reductions in cardiac output showed a similar pattern. Lactate concentrations and ratings of perceived exertion tended to be highest on metoprolol CR/ZOK, but these differences were inconsistent. We conclude that despite the changes in the cardiovascular system in these 50-70 year-old women, exercise tolerance was not greatly affected by beta-adrenoceptor blockade.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2312773     DOI: 10.1002/j.1552-4604.1990.tb03507.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension.

Authors:  M F Chen; C Y Yang; W J Chen; C M Lee; C C Wu; C S Liau; Y T Lee
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

Review 2.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.